Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0247 Transporter Info | ||||
| Gene Name | SLC29A1 | ||||
| Protein Name | Equilibrative nucleoside transporter 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs747199 | ||||
| Site of GPD | chr6:44226608 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>C | ||||
| Minor Allele Frequency | C=0.1478/740 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Gemcitabine | Drug Info | Breast Neoplasm | Correlated with the decreased drug response in patients (compare with Allele C) | [ 1] | |
| Paclitaxel | Drug Info | Breast Neoplasm | Correlated with the decreased drug response in patients (compare with Allele C) | [ 1] | |
| Genetic Polymorphism | rs760370 | ||||
| Site of GPD | chr6:44233216 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.2997/1501 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Gemcitabine | Drug Info | Breast Neoplasm | Correlated with the decreased drug response in patients (compare with allele G) | [ 1] | |
| Paclitaxel | Drug Info | Breast Neoplasm | Correlated with the decreased drug response in patients (compare with allele G) | [ 1] | |
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Gemcitabine | Drug Info | Pancreatic Neoplasm | Correlated with the decreased drug response in patients (compare with genotypes AA + AG) | [ 2] | |
| Ribavirin | Drug Info | Chronic Hepatitis C | Correlated with the increased drug response in patients (compare with genotypes AA + AG) | [ 3] | |
| Peginterferon alfa-2A | Drug Info | Chronic Hepatitis C | Correlated with the increased drug response in patients (compare with genotypes AA + AG) | [ 3] | |
| Peginterferon alfa-2B | Drug Info | Chronic Hepatitis C | Correlated with the increased drug response in patients (compare with genotypes AA + AG) | [ 3] | |
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Trifluridine | Drug Info | Colorectal Neoplasm | Correlated with the increased drug response in patients (compare with genotype AA) | [ 4] | |
| Tipiracil hydrochloride | N.A. | Colorectal Neoplasm | Correlated with the increased drug response in patients (compare with genotype AA) | [ 4] | |
| Genetic Polymorphism | rs9394992 | ||||
| Site of GPD | chr6:44228255 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.2973/1489 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | Drug Info | Pancreatic Neoplasm | Irrelevant to the increased drug response in patients (compare with Genotypes CT + TT) | [ 2] | |
| Genotypes CT + TT | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Trifluridine | Drug Info | Colorectal Neoplasm | Correlated with the increased drug response in patients (compare with genotype CC) | [ 4] | |
| Gemcitabine | Drug Info | Pancreatic Neoplasm | Correlated with the increased neutropenia risk in patients (compare with genotype CC) | [ 2] | |
| Tipiracil hydrochloride | N.A. | Colorectal Neoplasm | Correlated with the increased drug response in patients (compare with genotype CC) | [ 4] | |
| References | |||||
| 1 | Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer. 2014 Mar;50(4):698-705. | ||||
| 2 | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15;116(22):5325-35. | ||||
| 3 | Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis. 2010 Oct 15;202(8):1185-91. | ||||
| 4 | Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 Nov;86:197-206. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.